Summary

Targeted Therapeutics Market – Scope of Report
TMR’s report on the global targeted therapeutics market studies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the market during the forecast period from 2023 to 2031. The report provides revenue of the global targeted therapeutics market for the period 2017–2031, considering 2023 as the base year and 2031 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global targeted therapeutics market from 2023 to 2031.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players’ product literature, annual reports, press releases, and relevant documents to understand the targeted therapeutics market.

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global targeted therapeutics market.

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global targeted therapeutics market. These serve as valuable tools for existing market players as well as for entities interested in participating in the global targeted therapeutics market.

The report delves into the competitive landscape of the global targeted therapeutics market. Key players operating in the global targeted therapeutics market have been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global targeted therapeutics market profiled in this report.

Key Questions Answered in Global targeted therapeutics Market Report
• What is the sales/revenue generated by targeted therapeutics across all regions during the forecast period?
• What are the opportunities in the global targeted therapeutics market?
• What are the major drivers, restraints, opportunities, and threats in the market?
• Which regional market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2031?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the market positions of different companies operating in the global market?

Targeted Therapeutics Market – Research Objectives and Research Approach
The comprehensive report on the global targeted therapeutics market begins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global targeted therapeutics market in terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the market share for each of these at the end of 2031 has been provided. Such valuable insights enable market stakeholders in making informed business decisions for investment in the global targeted therapeutics market.

ページTOPに戻る

Table of Contents

1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Targeted Therapeutics Market
4. Market Overview
4.1. Introduction
4.1.1. Type Definition
4.1.2. Industry Evolution/Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Targeted Therapeutics Market Analysis and Forecast, 2017–2031
5. Key Insights
5.1. Pipeline Analysis
5.2. Key Type/Brand Analysis
5.3. Key Mergers & Acquisitions
5.4. COVID-19 Pandemic Impact on Industry
6. Global Targeted Therapeutics Market Analysis and Forecast, by Type
6.1. Introduction & Definition
6.2. Key Findings/Developments
6.3. Market Value Forecast, by Type, 2017–2031
6.3.1. Monoclonal Antibodies
6.3.1.1. Angiogenesis Inhibitors
6.3.1.2. HER-2 Targeted Agents
6.3.1.3. Anti-CD20 Monoclonal Antibodies
6.3.2. Small Molecule
6.3.2.1. Tyrosine Kinase Inhibitors
6.3.2.1.1. mTOR Inhibitors
6.3.2.1.2. PARP Inhibitors
6.4. Market Attractiveness Analysis, by Type
7. Global Targeted Therapeutics Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings/Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Breast Cancer
7.3.2. Colorectal Cancer
7.3.3. Leukemia
7.3.4. Lung Cancer
7.3.5. Lymphoma
7.3.6. Multiple Sclerosis
7.3.7. Renal Cancer
7.3.8. Wet Age-related Macular Degeneration
7.3.9. Others (Ovarian Cancer, Fallopian Tube cancer, Prostate Cancer, and Pancreatic Cancer)
7.4. Market Attractiveness Analysis, by Application
8. Global Targeted Therapeutics Market Analysis and Forecast, by Distribution Channel
8.1. Introduction & Definition
8.2. Key Findings/Developments
8.3. Market Value Forecast, by Distribution Channel, 2017–2031
8.3.1. Hospital Pharmacies
8.3.2. Retail Pharmacies
8.3.3. Online Pharmacies
8.4. Market Attractiveness Analysis, by Distribution Channel
9. Global Targeted Therapeutics Market Analysis and Forecast, by Region
9.1. Key Findings
9.2. Market Value Forecast, by Region, 2017–2031
9.2.1. North America
9.2.2. Europe
9.2.3. Asia Pacific
9.2.4. Latin America
9.2.5. Middle East & Africa
9.3. Market Attractiveness Analysis, by Region
10. North America Targeted Therapeutics Market Analysis and Forecast
10.1. Introduction
10.2. Key Findings
10.3. Market Value Forecast, by Type, 2017–2031
10.3.1. Monoclonal Antibodies
10.3.1.1. Angiogenesis Inhibitors
10.3.1.2. HER-2 Targeted Agents
10.3.1.3. Anti-CD20 Monoclonal Antibodies
10.3.2. Small Molecule
10.3.2.1. Tyrosine Kinase Inhibitors
10.3.2.1.1. mTOR Inhibitors
10.3.2.1.2. PARP Inhibitors
10.4. Market Value Forecast, by Application, 2017–2031
10.4.1. Breast Cancer
10.4.2. Colorectal Cancer
10.4.3. Leukemia
10.4.4. Lung Cancer
10.4.5. Lymphoma
10.4.6. Multiple Sclerosis
10.4.7. Renal Cancer
10.4.8. Wet Age-related Macular Degeneration
10.4.9. Others (Ovarian Cancer, Fallopian Tube cancer, Prostate
10.5. Market Value Forecast, by Distribution Channel, 2017–2031
10.5.1. Hospital Pharmacies
10.5.2. Retail Pharmacies
10.5.3. Online Pharmacies
10.6. Market Value Forecast, by Country, 2017–2031
10.6.1. U.S.
10.6.2. Canada
10.7. Market Attractiveness Analysis
10.7.1. By Type
10.7.2. By Application
10.7.3. By Distribution Channel
10.7.4. By Country
11. Europe Targeted Therapeutics Market Analysis and Forecast
11.1. Introduction
11.2. Key Findings
11.3. Market Value Forecast, by Type, 2017–2031
11.3.1. Monoclonal Antibodies
11.3.1.1. Angiogenesis Inhibitors
11.3.1.2. HER-2 Targeted Agents
11.3.1.3. Anti-CD20 Monoclonal Antibodies
11.3.2. Small Molecule
11.3.2.1. Tyrosine Kinase Inhibitors
11.3.2.1.1. mTOR Inhibitors
11.3.3. 11.3.2.1.2 PARP Inhibitors
11.4. Market Value Forecast, by Application, 2017–2031
11.4.1. Breast Cancer
11.4.2. Colorectal Cancer
11.4.3. Leukemia
11.4.4. Lung Cancer
11.4.5. Lymphoma
11.4.6. Multiple Sclerosis
11.4.7. Renal Cancer
11.4.8. Wet Age-related Macular Degeneration
11.4.9. Others (Ovarian Cancer, Fallopian Tube cancer, Prostate
11.5. Market Value Forecast, by Distribution Channel, 2017–2031
11.5.1. Hospital Pharmacies
11.5.2. Retail Pharmacies
11.5.3. Online Pharmacies
11.6. Market Value Forecast, by Country/Sub-region, 2017–2031
11.6.1. Germany
11.6.2. U.K.
11.6.3. France
11.6.4. Italy
11.6.5. Spain
11.6.6. Rest of Europe
11.7. Market Attractiveness Analysis
11.7.1. By Type
11.7.2. By Application
11.7.3. By Distribution Channel
11.7.4. By Country/Sub-region
12. Asia Pacific Targeted Therapeutics Market Analysis and Forecast
12.1. Introduction
12.2. Key Findings
12.3. Market Value Forecast, by Type, 2017–2031
12.3.1. Monoclonal Antibodies
12.3.1.1. Angiogenesis Inhibitors
12.3.1.2. HER-2 Targeted Agents
12.3.1.3. Anti-CD20 Monoclonal Antibodies
12.3.2. Small Molecule
12.3.2.1. Tyrosine Kinase Inhibitors
12.3.2.1.1. mTOR Inhibitors
12.3.2.1.2. PARP Inhibitors
12.4. Market Value Forecast, by Application, 2017–2031
12.4.1. Breast Cancer
12.4.2. Colorectal Cancer
12.4.3. Leukemia
12.4.4. Lung Cancer
12.4.5. Lymphoma
12.4.6. Multiple Sclerosis
12.4.7. Renal Cancer
12.4.8. Wet Age-related Macular Degeneration
12.4.9. Others (Ovarian Cancer, Fallopian Tube cancer, Prostate
12.5. Market Value Forecast, by Distribution Channel, 2017–2031
12.5.1. Hospital Pharmacies
12.5.2. Retail Pharmacies
12.5.3. Online Pharmacies
12.6. Market Value Forecast, by Country/Sub-region, 2017–2031
12.6.1. China
12.6.2. Japan
12.6.3. India
12.6.4. Australia & New Zealand
12.6.5. Rest of Asia Pacific
12.7. Market Attractiveness Analysis
12.7.1. By Type
12.7.2. By Application
12.7.3. By Distribution Channel
12.7.4. By Country/Sub-region
13. Latin America Targeted Therapeutics Market Analysis and Forecast
13.1. Introduction
13.2. Key Findings
13.3. Market Value Forecast, by Type, 2017–2031
13.3.1. Monoclonal Antibodies
13.3.1.1. Angiogenesis Inhibitors
13.3.1.2. HER-2 Targeted Agents
13.3.1.3. Anti-CD20 Monoclonal Antibodies
13.3.2. Small Molecule
13.3.2.1. Tyrosine Kinase Inhibitors
13.3.2.1.1. mTOR Inhibitors
13.3.2.1.2. PARP Inhibitors
13.4. Market Value Forecast, by Application, 2017–2031
13.4.1. Breast Cancer
13.4.2. Colorectal Cancer
13.4.3. Leukemia
13.4.4. Lung Cancer
13.4.5. Lymphoma
13.4.6. Multiple Sclerosis
13.4.7. Renal Cancer
13.4.8. Wet Age-related Macular Degeneration
13.4.9. Others (Ovarian Cancer, Fallopian Tube cancer, Prostate
13.5. Market Value Forecast, by Distribution Channel, 2017–2031
13.5.1. Hospital Pharmacies
13.5.2. Retail Pharmacies
13.5.3. Online Pharmacies
13.6. Market Value Forecast, by Country/Sub-region, 2017–2031
13.6.1. Brazil
13.6.2. Mexico
13.6.3. Rest of Latin America
13.7. Market Attractiveness Analysis
13.7.1. By Type
13.7.2. By Application
13.7.3. By Distribution Channel
13.7.4. By Country/Sub-region
14. Middle East & Africa Targeted Therapeutics Market Analysis and Forecast
14.1. Introduction
14.2. Key Findings
14.3. Market Value Forecast, by Type, 2017–2031
14.3.1. Monoclonal Antibodies
14.3.1.1. Angiogenesis Inhibitors
14.3.1.2. HER-2 Targeted Agents
14.3.1.3. Anti-CD20 Monoclonal Antibodies
14.3.2. Small Molecule
14.3.2.1. Tyrosine Kinase Inhibitors
14.3.2.1.1. mTOR Inhibitors
14.3.2.1.2. PARP Inhibitors
14.4. Market Value Forecast, by Application, 2017–2031
14.4.1. Breast Cancer
14.4.2. Colorectal Cancer
14.4.3. Leukemia
14.4.4. Lung Cancer
14.4.5. Lymphoma
14.4.6. Multiple Sclerosis
14.4.7. Renal Cancer
14.4.8. Wet Age-related Macular Degeneration
14.4.9. Others (Ovarian Cancer, Fallopian Tube cancer, Prostate
14.5. Market Value Forecast, by Distribution Channel, 2017–2031
14.5.1. Hospital Pharmacies
14.5.2. Retail Pharmacies
14.5.3. Online Pharmacies
14.6. Market Value Forecast, by Country/Sub-region, 2017–2031
14.6.1. GCC Countries
14.6.2. South Africa
14.6.3. Rest of Middle East & Africa
14.7. Market Attractiveness Analysis
14.7.1. By Type
14.7.2. By Application
14.7.3. By Distribution Channel
14.7.4. By Country/Sub-region
15. Competition Landscape
15.1. Market Player - Competitive Matrix (by Tier and Size of Companies)
15.2. Market Share Analysis, by Company (2022)
15.3. Company Profiles
15.3.1. Sanofi
15.3.1.1. Company Overview
15.3.1.2. Type Portfolio
15.3.1.3. SWOT Analysis
15.3.1.4. Financial Overview
15.3.1.5. Strategic Overview
15.3.2. GlaxoSmithKline plc
15.3.2.1. Company Overview
15.3.2.2. Type Portfolio
15.3.2.3. SWOT Analysis
15.3.2.4. Financial Overview
15.3.2.5. Strategic Overview
15.3.3. Takeda Pharmaceutical Company Ltd.
15.3.3.1. Company Overview
15.3.3.2. Type Portfolio
15.3.3.3. SWOT Analysis
15.3.3.4. Financial Overview
15.3.3.5. Strategic Overview
15.3.4. Merck & Co., Inc.
15.3.4.1. Company Overview
15.3.4.2. Type Portfolio
15.3.4.3. SWOT Analysis
15.3.4.4. Financial Overview
15.3.4.5. Strategic Overview
15.3.5. Novartis AG
15.3.5.1. Company Overview
15.3.5.2. Type Portfolio
15.3.5.3. SWOT Analysis
15.3.5.4. Financial Overview
15.3.5.5. Strategic Overview
15.3.6. Pfizer Inc.
15.3.6.1. Company Overview
15.3.6.2. Type Portfolio
15.3.6.3. SWOT Analysis
15.3.6.4. Financial Overview
15.3.6.5. Strategic Overview
15.3.7. F. Hoffmann-La Roche Ltd.
15.3.7.1. Company Overview
15.3.7.2. Type Portfolio
15.3.7.3. SWOT Analysis
15.3.7.4. Financial Overview
15.3.7.5. Strategic Overview
15.3.8. AstraZeneca
15.3.8.1. Company Overview
15.3.8.2. Type Portfolio
15.3.8.3. SWOT Analysis
15.3.8.4. Financial Overview
15.3.8.5. Strategic Overview
15.3.9. Seagen, Inc.
15.3.9.1. Company Overview
15.3.9.2. Type Portfolio
15.3.9.3. SWOT Analysis
15.3.9.4. Financial Overview
15.3.9.5. Strategic Overview
15.3.10. Bayer AG
15.3.10.1. Company Overview
15.3.10.2. Type Portfolio
15.3.10.3. SWOT Analysis
15.3.10.4. Financial Overview
15.3.10.5. Strategic Overview
15.3.11. Amgen, Inc.
15.3.11.1. Company Overview
15.3.11.2. Type Portfolio
15.3.11.3. SWOT Analysis
15.3.11.4. Financial Overview
15.3.11.5. Strategic Overview
15.3.12. Bristol-Myers Squibb Company
15.3.12.1. Company Overview
15.3.12.2. Type Portfolio
15.3.12.3. SWOT Analysis
15.3.12.4. Financial Overview
15.3.12.5. Strategic Overview